We always think of our customers with an open mind
Press Release
NTL, CerviCARE® AI Special Lecture to Participate in TGCS 2023 in Thailand
Author
엔티엘헬스케어
Date
2023-08-09 16:04
Views
221
Professor Woong Ju from Ewha Womans University Seoul Hospital Invited to give a keynote lecture, receiving great response.
(Image=Professor Woong Ju from Ewha Womans University Seoul Hospital, invited to give a keynote lecture at the TGCS 2023 conference.)
Tae-hee Kim, CEO of NTL Healthcare, a leading pioneer in the field of artificial intelligence (AI) for cervical cancer, announced that she was specially invited to participate in the 'TGCS Annual Meeting 2023' held in Chiang Mai, Thailand.
TGCS is an international academic conference organized by the Thai Society of Gynecologic Oncology, with the theme "Improvement for Better Health in Gynecologic Cancers." The conference held from August 4th to 6th, for 3 days, and was attended by over 300 gynecologic oncology specialists.
The highlight of this conference was the special lecture on CerviCARE®, an AI-based cervical cancer early screening medical device that utilizes big data and provides results with high sensitivity within seconds.
Professor Woong Ju from Ewha Womans University Seoul Hospital, who was invited as a special guest lecturer at the Luncheon Symposium that lasted for an hour, gave a presentation on the topic of "The usefulness of CerviCARE® AI system as a cervical cancer screening." He mentioned the learning and utilization of AI data in the medical field.
In particular, he emphasized the need for thorough validation and responsibility in the use of AI in the medical field, as biased data learning can lead to accountability for the results. He said, "CerviCARE® AI developed by NTL not only yields high accuracy and fast results based on validated data but also distinguishes between normal and abnormal results, providing information on morphological abnormalities. It is an AI software screening medical device approved by the Ministry of Food and Drug Safety, and I believe it will be a great help to women suffering from cervical cancer worldwide, including Thailand."
Meanwhile, NTL, a leading global company in the field of cervical cancer screening, has been leading the domestic and international market for cervical cancer screening medical devices for 27 years. NTL has signed export contracts with countries including Mongolia, Vietnam, Costa Rica, and Brazil, and are conducting research in accordance with the cervical cancer screening guidelines of each country, solidifying their position as a global leader in this field.
(Image=Chairman of TGCS ‘Wichai Termrungruanglert’ (center), CEO of NTL Healthcare ‘Tae-hee Kim’ (left), and Professor Woong Ju (right), and employees of Winnergy Medical, the Thai partner of CerviCARE® AI)
Tae-hee Kim (CEO of NTL Healthcare), expressed her expectations for CerviCARE® AI to bring about revolutionary changes in remote healthcare services and the introduction of AI in the medical field, particularly in cervical cancer screening. She stated, “This TGCS event has provided a great opportunity to showcase the excellence of CerviCARE® AI.”
(Image=Professor Woong Ju from Ewha Womans University Seoul Hospital, invited to give a keynote lecture at the TGCS 2023 conference.)
Tae-hee Kim, CEO of NTL Healthcare, a leading pioneer in the field of artificial intelligence (AI) for cervical cancer, announced that she was specially invited to participate in the 'TGCS Annual Meeting 2023' held in Chiang Mai, Thailand.
TGCS is an international academic conference organized by the Thai Society of Gynecologic Oncology, with the theme "Improvement for Better Health in Gynecologic Cancers." The conference held from August 4th to 6th, for 3 days, and was attended by over 300 gynecologic oncology specialists.
The highlight of this conference was the special lecture on CerviCARE®, an AI-based cervical cancer early screening medical device that utilizes big data and provides results with high sensitivity within seconds.
Professor Woong Ju from Ewha Womans University Seoul Hospital, who was invited as a special guest lecturer at the Luncheon Symposium that lasted for an hour, gave a presentation on the topic of "The usefulness of CerviCARE® AI system as a cervical cancer screening." He mentioned the learning and utilization of AI data in the medical field.
In particular, he emphasized the need for thorough validation and responsibility in the use of AI in the medical field, as biased data learning can lead to accountability for the results. He said, "CerviCARE® AI developed by NTL not only yields high accuracy and fast results based on validated data but also distinguishes between normal and abnormal results, providing information on morphological abnormalities. It is an AI software screening medical device approved by the Ministry of Food and Drug Safety, and I believe it will be a great help to women suffering from cervical cancer worldwide, including Thailand."
Meanwhile, NTL, a leading global company in the field of cervical cancer screening, has been leading the domestic and international market for cervical cancer screening medical devices for 27 years. NTL has signed export contracts with countries including Mongolia, Vietnam, Costa Rica, and Brazil, and are conducting research in accordance with the cervical cancer screening guidelines of each country, solidifying their position as a global leader in this field.
(Image=Chairman of TGCS ‘Wichai Termrungruanglert’ (center), CEO of NTL Healthcare ‘Tae-hee Kim’ (left), and Professor Woong Ju (right), and employees of Winnergy Medical, the Thai partner of CerviCARE® AI)
Tae-hee Kim (CEO of NTL Healthcare), expressed her expectations for CerviCARE® AI to bring about revolutionary changes in remote healthcare services and the introduction of AI in the medical field, particularly in cervical cancer screening. She stated, “This TGCS event has provided a great opportunity to showcase the excellence of CerviCARE® AI.”
